BLA 125117 · Biomarin
Naglazyme
Galsulfase · Injection · Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
May 31, 2005
Approved uses
4
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 1 recruiting
FAERS reports
3,877
2,558 serious, 352 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate NAGLAZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue NAGLAZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...
What it is approved for
From the label in effect Sep 18, 2024.
NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity. NAGLAZYME is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity. ( 1 )
Mechanism: Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of GAG. MPS VI is characterized by the absence or marked reduction in N-acetylgalactosamine 4-sulfatase. The sulfatase activity deficiency results in the accumulation of the GAG substrate, dermatan sulfate, throughout the body. This accumulation leads to widespread cellular, tissue, and organ dysfunction. NAGLAZYME is intended to provide an exogenous enzyme that will be taken up into lysosomes and increase the catabolism of GAG. Galsulfase uptake by cells into lysosomes...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 28, 2011 Supplement 88 · Efficacy OrphanLabelLetter
- Apr 28, 2011 Supplement 86 · Efficacy LabelLetter
- Apr 28, 2011 Supplement 90 · Efficacy OrphanLabelLetter
- May 31, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- NAGLAZYME · GALSULFASE 5MG/5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Galsulfase" as an intervention, any sponsor and status, largest first.
University of California, San FranciscoAcademic, hospital or other
NCT04532047 · 10 participants (planned) · Start Jul 1, 2021 · Primary completion Jul 31, 2031
Drug: Aldurazyme (laronidase) · For: MPS I; MPS II; MPS IVA and 6 more
Sites: San Francisco, California
BioMarin PharmaceuticalBioMarin (BMRN)
NCT00299000 · 4 participants · Start May 2006 · Primary completion Apr 2009
Drug: Naglazyme · For: Mucopolysaccharidosis VI; Maroteaux-Lamy Syndrome
Sites: Los Angeles, California; Oakland, California; Lyon, France · 4 sites in all
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
NCT02156674 · 1 participants · Start Jan 26, 2016 · Primary completion Dec 1, 2019
Drug: Naglazyme® · For: Maroteaux-Lamy Syndrome
Sites: Minneapolis, Minnesota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia420
- pneumonia307
- cough228
- dyspnoea195
- spinal cord compression161
- vomiting133
- oxygen saturation decreased131
- fatigue113
- headache95
- pain92
- influenza91
- death90
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 19 |
| 2009 | 38 |
| 2010 | 68 |
| 2011 | 113 |
| 2012 | 126 |
| 2013 | 113 |
| 2014 | 483 |
| 2015 | 335 |
| 2016 | 224 |
| 2017 | 233 |
| 2018 | 239 |
| 2019 | 255 |
| 2020 | 250 |
| 2021 | 266 |
| 2022 | 289 |
| 2023 | 213 |
| 2024 | 224 |
| 2025 | 240 |
| 2026 | 148 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Naglazyme (Galsulfase)
2024 spending
$5.1M
Beneficiaries
n/a
42 claims
Per beneficiary
n/a
$447.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,109,419 |
| 2021 | $6,204,188 |
| 2022 | $5,999,848 |
| 2023 | $6,148,670 |
| 2024 | $5,075,599 |
Part B: Naglazyme (Galsulfase) · HCPCS J1458
2024 spending
$393K
Beneficiaries
n/a
23 claims
Per beneficiary
n/a
2024 ASP limit $472.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $746,056 |
| 2021 | $445,531 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $393,377 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ, Atallah ÁN, da Silva EM · Cochrane Database Syst Rev 2016 · Research Support, Non-U.S. Gov't, Systematic Review
- Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?
Pitz S, Ogun O, Arash L, et al. · Graefes Arch Clin Exp Ophthalmol 2009 · Clinical Trial, Phase III, Controlled Clinical Trial
- Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI.
Harmatz PR, Garcia P, Guffon N, et al. · J Inherit Metab Dis 2014 · Clinical Trial, Phase IV, Multicenter Study
- Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ, Atallah ÁN, da Silva EM · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P, Hendriksz CJ, Lampe C, et al. · Mol Genet Metab 2017 · Clinical Trial, Research Support, N.I.H., Extramural
- Efficacy of different treatment strategies in patients with mucopolysaccharidosis: a systematic review and network meta-analysis of randomized controlled trials.
Huang L, Wu J, Tang B, et al. · Orphanet J Rare Dis 2025 · Network Meta-Analysis, Systematic Review
Sponsor: BioMarin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.